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Abstract
Background: B cell non Hodgkin lymphomas account for the majority of lymphomas in Uganda. The commonest is 
endemic Burkitt lymphoma, followed by diffuse large-B-cell lymphoma (DLBCL). There has been an increase in 
incidence of malignant lymphoma since the onset of the HIV/AIDS pandemic. However, the possible linkages of HHV8 
and EBV to the condition of impaired immunity present in AIDS are still not yet very clearly understood.
Objectives: 1. To describe the prevalence of Epstein-Barr virus, Human Herpes virus 8 and Human Immunodeficiency 
Virus-1 in B cell non Hodgkin lymphoma biopsy specimens in Kampala, Uganda.
2. To describe the histopathology of non Hodgkin lymphoma by HIV serology test result in Kampala, Uganda
Method: Tumour biopsies specimens from 119 patients with B cell non Hodgkin lymphoma were classified according 
to the WHO classification. Immunohistochemistry was used for detection of HHV8 and in situ hybridization with 
Epstein Barr virus encoded RNA (EBER) for EBV. Real time and nested PCR were used for the detection of HIV.
The patients from whom the 1991-2000 NHL biopsies had been taken did not have HIV serology results therefore 145 
patients biopsies where serology results were available were used to describe the association of HIV with non Hodgkin 
lymphoma type during 2008-2009.
Results: In this study, the majority (92%) of the Burkitt lymphomas and only 34.8% of the diffuse large B cell 
lymphomas were EBV positive. None of the precursor B lymphoblastic lymphomas or the mantle cell lymphomas 
showed EBV integration in the lymphoma cells.
None of the Burkitt lymphoma biopsies had HIV by PCR. Of the 121 non Hodgkin B cell lymphoma patients with HIV 
test results, 19% had HIV. However, only 1(0.04%) case of Burkitt lymphoma had HIV. All the tumours were HHV8 
negative.
Conclusions: The majority of the Burkitt lymphomas and two fifths of the diffuse large B cell lymphomas had EBV. All 
the tumours were HHV8 negative. Generally, the relationship of NHL and HIV was weaker than what has been reported 
from the developed countries. We discuss the role of these viruses in lymphomagenesis in light of current knowledge.
Introduction
The frequency of non Hodgkin lymphomas (NHLs) has
increased since the beginning of the HIV/AIDS pandemic
in the early 1980s[1]. However, recently, studies have
shown an association of non Hodgkin lymphomas
(NHLs) with two gamma herpes viruses, Epstein-Barr
virus (EBV) and Kaposi sarcoma herpes virus (KSHV)/
Human herpes virus-8(HHV 8)[2,3].
EBV is important in the causation of Burkitt lymphoma
(BL), Hodgkin lymphoma and other non Hodgkin lym-
phomas whereas HHV8 serves as an important
co-factor in the pathogenesis of primary effusion lym-
phoma (PEL) and large B cell lymphomas arising in
patients with multicentric Castleman's disease who are
profoundly immunosuppressed[4,5].
HIV associated lymphomas are high grade and of B cell
origin. They are mainly extranodal and have poor prog-
nosis.
They are broadly categorised as systemic lymphomas
and primary central nervous system lymphomas. The
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systemic lymphomas include Burkitt lymphoma, diffuse
large B cell lymphoma with immunoblastic (IB) morphol-
ogy, HHV8+ primary effusion lymphoma (PEL) and its
solid variant and plasmablastic lymphoma (PBL)[6].
In Western Europe and America, approximately 50-
70% of HIV associated-DLBCL are EBV positive and
express the transforming latent membrane protein-
1(LMP-1). LMP-1 plays a critical role in the transforma-
tion of B lymphocytes. The effect of EBV LMP-1 in
DLBCL is strongest in tumors representing a post germi-
nal centre differentiation profile[7].
Since the majority of HIV -associated DLBCL are EBV
positive, the defective T-cell immunity created by the
HIV infection leads to promotion of EBV driven B cell
proliferation hence lymphoma. However the disparities
between EBV driven lymphoproliferations in transplant
patients and those in HIV patients suggests that other
factors are necessary for genetic damage in HIV associ-
ated-DLBCL[2].
HIV related BL in Western Europe and America have
30-60% EBV positivity. However, unlike DLBCL, the
transforming EBV LMP-1 is not expressed in BL.
EBV supports BL tumour development. Epstein Barr
nuclear antigen-1 (EBNA-1), a viral protein required for
the replication and maintenance of the latent viral epi-
somal DNA is consistently found in BL cells[7].
In vitro studies have shown that EBNA-1 transgenic
mice develop B cell lymphoma with a very long latency,
and EBNA-1 and c-myc may cooperate in its develop-
ment[2,8].
The presence of latent EBV in B cells promotes genetic
instability and therefore suggests that latent EBV could
contribute to genetic alterations required for develop-
ment of BL. In addition, some latent EBV transcription
patterns found in BL produce viral proteins that are likely
to protect BL cells from apoptosis induced by deregulated
c-myc expression[9,10].
Given the strong apoptotic effects caused by over
expression of c-myc, the role of EBV in some cases of BL
is thought to be that of protecting BL cells from this side
effect of c-myc translocation[11].
EBV-associated B cell lymphomas are caused by muta-
tions and translocations of genes at various stages of dif-
ferentiation and associated with expression of EBV latent
genes. EBV latency 3 type antigens, such as the trans-
forming latent membrane protein-1 and 2 and EBNA-2,
have transformed cultured cells. In contrast, the majority
of primary central nervous system lymphomas (PCNSL)
are large cell, monoclonal B cell lymphomas that are clon-
ally infected with EBV, although typically lacking the c-
myc translocation[12].
The oncogenic potential of HHV8 in B cells is however
less understood[13]. However HHV8 is an important fac-
tor in the oncogenesis of primary effusion lymphoma
(PEL). Studies have shown that when B lymphocytes are
infected by HHV8 in vitro, B cell transformation does not
occur [14].
Cell lines have been derived from PEL specimens
infected with HHV8 and they are being used for studying
t h e  m o l e c u l a r  e f f e c t s  o f  H H V 8  g e n e  e x p r e s s i o n  o n  B
cells[15]. Genomic studies have shown that multiple cop-
ies (50-150 copies/cell) of episomal HHV8 genomes
occur in PEL cells and when tested for presence of HHV8,
all PEL cells were infected with HHV8 hence suggesting a
role of HHV8 in PEL[15].
There is clonal expansion of the HHV8 infected cells
with latent gene expression that causes neoplastic trans-
formation through mechanisms of increased proliferation
and impaired apoptosis. However , the true role of lytic
genes during neoplastic transformation in vivo is not
known[16].
In most cells, the latent viral gene expression pattern
involves the expression of the latency associated nuclear
antigen(LANA), a viral D-type cyclin homologue (vcyc), a
viral homologue of FLICE inhibitory protein (vFLIP), a
pre-miRNA transcript encoding 11 viral miRNAs, as well
as vIRF3/K10.5/LANA-2. In addition a homologue of IL-
6 is also expressed in some PEL cells[17].
Human immunodeficiency virus (HIV) is a lentivirus (a
member of the retrovirus family). Historically, the retro-
viruses, have generally not been considered as causes of
human cancer. The pathogenesis of AIDS-associated
malignancies is thought to be the result of an opportunis-
tic proliferation due to an oncogenic stimuli and a
depressed immune system[18].
HIV is now thought to have a more direct transforming
role than earlier thought as evidenced by studies done by
McGrath in Kaposi sarcoma lesions where he found HIV-
1 integrated in macrophages surrounding the early KS
lesion but not in later more developed lesions[18,19].
The integrated provirus and the expressed HIV-1 gene
products are thought to stimulate the surrounding mac-
rophages to produce activating cytokines and hence
cause proliferation[20].
A common integration site of HIV-1 is on the c-fes/fps
oncogene. This is relevant to tumorigenesis because c-fes/
fps oncogene encodes a protein-tyrosine kinase that has
been implicated in controlling transformation of hae-
mopoietic cells. The 92kD c-fes/fps  protein signals
through macrophage activating cytokines (IL-3, GM-CSF,
and M-CSF). Integrated macrophages could lead to a
complicated interaction with B-cells and T-cells via cell-
cell signalling. Up regulation of c-fes/fps  signalling has
been shown in cells with the integrated HIV-1 provirus.
These studies were however done in non B cell lympho-
mas but however prove that these lymphomas developed
non -randomly[18,21].Tumwine et al. Infectious Agents and Cancer 2010, 5:12
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HIV infected macrophages simulate an environment
that is necessary for oncogenesis by up regulating growth
factors, M-CSF, IL-8, IL-6, IL-10 and may become clonal.
The paracrine effects lead to the surrounding B cells
being stimulated into activation and proliferation[18,21].
In sub Saharan Africa, EBV, HHV8, HIV are endemic.
This paper discusses the role of these viruses in lym-
phomagenesis in light of current knowledge.
Methods
Study design
A cross sectional descriptive design was used to describe
the prevalence of Epstein Barr virus(EBV), Human Her-
pes virus 8(HHV8) and Human immunodeficiency virus-
1(HIV-1) in the B cell non Hodgkin lymphoma biopsy
specimens (1991-2000). We also described the histopa-
thology of non Hodgkin lymphomas (2008-2009) by HIV
serology test result. Routine HIV counselling and testing
became available in 2004 which was well after the initial
study period (1991-2000).
Histopathology
Six hundred formalin fixed paraffin embedded tissue
blocks with a diagnosis of non Hodgkin lymphoma were
collected from the archive of the Department of Pathol-
ogy, School of Biomedical Sciences, Makerere University
College of Health Sciences from 1991-2000, 2008-2009.
They were reassessed, stained with haematoxylin and
eosin and Giemsa as previously described[22] Only 129
(1991-2000) were suitable for tissue micro array con-
struction. The corresponding patient clinical case notes
and histology report forms were also retrieved.
During 2008-2009, 142 biopsies from patients with
known HIV serology test results were also analysed.
Immunohistochemistry
Tissue micro arrays were constructed from the individual
paraffin blocks and then subjected to monoclonal anti-
bodies (CD3, CD5, CD10, CD20, CD30, CD38, CD79a,
BCl-2, BCl-6, Ki-67, CD138, IRTA-1, MUM-1/IRF4,
LANA-1) as previously described[22].
In situ hybridization
EBV was detected by looking for the presence of EBV
encoded RNA (EBER). It was assayed using in situ
hybridisation with a FITC labelled probe to EBER-1 and 2
(Dako Y0017) and mouse anti-FITC (Dako M0878), rab-
bit anti-mouse serum and APAAP complexes as
described previously[22]. Positive and negative controls
were run concurrently.
Polymerase chain reaction (PCR) for detection of HIV in 
formalin fixed paraffin embedded tissue blocks
DNA was extracted from the paraffin blocks as previously
described [22]and Real time-PCR and nested PCR were
used to detect the presence of HIV-1 [5], by looking for
adequate preservation of the PLZF gene (300 bp).
a) PCR HIV-1 env NESTED
Amplification reactions were carried out in an automated
thermocycler (mastercycler eppendorf) according to the
following PCR protocol. Each PCR reaction included 100
ng of DNA, 25 μM of each specific primers (gene env of
HIV-1), 0,2 mmol/L dNTP, PCR buffer 10× with MgCl 2
(Invitrogen), MgCl 2  25 mM and Taq pol. 5Uμ. The
cycling parameters were as follows: One cycle of denatur-
ation, annealing and extension were carried out at 94°C
for 1 min, 62°C for 10 sec, 72°C for 10 sec respectively.
Secondly, 40 cycles of denaturation, annealing and
extension were carried out at 94°C for 10 sec, 94°C for 10
sec, 94°C for 10 sec respectively. Two more cycles of
extension were carried out at 72°C for 7 min and 4°C
respectively.
The positive and negative controls were DNA extract
from 8E5LAV cells and DNA extract from Jurkat respec-
tively.
b) Real Time PCR protocol
The specific primers for gene fragment: gag HIV-1. The
Real-Time reagent used was Quantitect SYBR Green PCR
kit (Qiagen) according to the manufacturer's instructions.
Amplification reactions were done in LightCycler
Instrument Roche software analysis: LightCycler 5.3.2.
The positive and negative controls were DNA extract
from 8E5LAV cells and DNA extract from Jurkat respec-
tively.
The cycling parameters were as follows Taq Activation
(Hot-Start) at 95°C for 15 min followed by 45 cycles of
amplification for denaturation at 94°C for 10 sec, Anneal-
ing at 55°C for 30 sec, extension at 72°C for 30 sec and
analysis temperature 78°C for 3 sec*
* To exclude unspecific products and dimer primers.
The probes used for these analyses explored the gag
and env regions and spanned 142 and 248 base pairs
respectively [6].
Microscopy
Slides were mounted with a glass cover slip and analyzed
with an Olympus BX61 microscope (Olympus, Tokyo,
Japan).
Data management and analysis
Data were collected and entered into the computer using
EPI INFO software (supplied by CDC and WHO) for
storage and initial analysis. Further analysis was done
using SPSS software (SPSS, Chicago, IL)[23]. The data
were summarized in frequency tables and graphs. For
continuous variables such as age, the relevant measures
of central tendency (means for normally distributed data
and medians and interquartile ranges for skewed data)
were used to explore the data. Fisher exact test was usedTumwine et al. Infectious Agents and Cancer 2010, 5:12
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for comparison of frequencies. The Mann-Whitney U
test was used for unpaired comparison of continuous
variables. A p value of less than .05 was considered signif-
icant[24].
Ethical considerations
Permission to conduct the study and ethical clearance
were obtained from the Research and Ethics committee
of the Faculty of Medicine, Makerere University. A waiver
of consent to use the patients' de linked HIV serology
data was also obtained.
Results
Of the 129 samples used for TMA construction, 10 cases
(8%) were excluded from the study. Two were reclassified
as lymphocyte depleted classic Hodgkin lymphoma and 2
others as anaplastic large cell lymphoma after immuno-
histochemistry. In the other 6 cases, the core biopsy was
not representative enough of neoplastic tissue.
A total of 119 non Hodgkin B cell lymphoma biopsies
were analyzed. According the 2001 WHO classification of
haematopoietic and lymphoid neoplasms, they were clas-
sified as: 95 (79.8%) Burkitt lymphoma, 19 (16.0%) diffuse
large B cell lymphoma, 4 (3.4%) mantle cell lymphoma
and 1(0.84%) precursor B lymphoblastic lymphoma.
Distribution of EBV by lymphoma type
Of the 119 B-non Hodgkin lymphomas, only 109 had
EBV test results by in situ hybridisation,10 were not well
preserved and internal controls could not be detected
and were therefore excluded from the final analysis.
Eighty seven (79.8%) cases tested positive for EBV and
22(20.2%) tested negative.
Of these, 86 were Burkitt lymphoma, of whom 79
(91.9%) tested EBV positive and 7 (8.1%) were EBV nega-
tive.
Among the diffuse large B cell lymphomas 18 had EBV
test results. Eight (44.4%) were EBV positive and 10
(55.6%) EBV negative (Table 1).
Burkitt lymphoma cases were more likely to have a pos-
itive EBV result: OR 4.9 (95% CI 2.0-11.7).
Distribution of EBV by age and gender
Of the 105 non Hodgkin lymphomas with gender and
EBV results, 70 (66.7%) were male and 35 (33.3%) were
female. Seventeen (24.3%) of the males were EBV nega-
tive and 53 (75.7%) were EBV positive; 5 (13.5%) of the
females were EBV negative and 32 (86.5%) were EBV pos-
itive. The difference was not statistically significant. (Fig-
ure 1)
Of those that were aged less than ten years, 3 (5.5%)
were EBV negative and 52 (94.5%) were EBV positive. In
the more than 10 year age group 16 (33.3%) were EBV
negative and 32 (66.7%) were EBV positive. The children
below ten years of age were more likely to test positive for
EBV and this was statistically significant OR 1.42 (95% CI
1.2-1.8), p = 0.001 (Figure 2)
Distribution of EBV by anatomical site
As regards the distribution of EBV by primary anatomical
site of disease, the following were EBV positive; all the 17
tumours arising in the abdomen, 7 (87.5%) of the 8
tumours arising in the jaw, 15 (60%) of the 25 tumours
arising in the lymph nodes, 18 of the 19 (94.7%) gonad
tumors, all the 3 tumours arising in the kidney and finally
all six tumours with unspecified sites of origin.
HHV 8 association with non Hodgkin B cell lymphoma
None of the cases studied had HHV 8.
HIV association in Burkitt lymphoma biopsy samples
Since routine counselling and testing for HIV in lym-
phoma patients was not available during the initial study
period we sought to find out if any of the Burkitt lym-
phoma biopsies had HIV. After extracting DNA from the
formalin fixed paraffin embedded tissue blocks we used
PCR to assess for presence of HIV. None of the 95 Burkitt
lymphoma biopsies (1991-2000) showed HIV integration.
HIV serology association with non Hodgkin B cell 
lymphoma
In order to evaluate the relationship between HIV and
other non Hodgkin lymphomas, we prospectively analy-
Table 1: Distribution of non Hodgkin lymphoma types by Epstein Barr (EBER) test result, Makerere University, 1990-2000
Lymphoma type EBER RESULT Total
Positive (%) Negative (%)
Burkitt lymphoma 79(91.9) 7(8.1) 86
Diffuse large B cell lymphoma 8(44.4) 10(55.6) 18
Precursor B lymphoblastic lymphoma 0(0.0) 1(100) 1
Mantle cell lymphoma 0(0.0) 4(100) 4
Total 87(79.8) 22 (20.2) 109
BL cases were more likely to test positive for EBV than the others, OR 4.9(95% CI 2.0 - 11.7) p < 0.01)Tumwine et al. Infectious Agents and Cancer 2010, 5:12
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sed 145 lymphomas seen in the department of Pathology,
Makerere University College of Health Sciences during
the period 2008-2009 when routine HIV counselling and
testing was available.
Of the 145 patients with non Hodgkin lymphoma, 121/
145 (83%) had an HIV serology test result. Twenty three
(19%) tested HIV positive, 98 tested negative.
According the 2001 WHO classification of haematopoi-
etic and lymphoid neoplasms, they were classified as: 21/
23 (91.3%) diffuse large B cell lymphoma, 1 Burkitt lym-
phoma and 1 small lymphocytic lymphoma. Most of the
patients with DLBCLs were adults 17/21(81%) and had
abdominal disease 11/21(52%).
Discussion
Epstein Barr virus (EBV), human herpes virus 8(HHV 8)
and the Human immunodeficiency virus (HIV) are part
of the pathogenesis of a wide range of malignant lympho-
mas[2]. EBV is ubiquitous in the general human popula-
tion and in Africa, children are infected quite early[25].
The prevalence of HHV 8 varies with geographical loca-
tion and is high in the tropics[26,27].
The HIV pandemic in Africa has led to an increase in
the incidence of tumors associated with these viruses,
Kaposi sarcoma and non Hodgkin lymphoma[28].
Previous studies have shown high prevalence of these
viruses in sub Saharan Africa. We sought to describe the
prevalence of these viruses in biopsy specimens of Ugan-
dan non Hodgkin lymphomas[29].
Only 121 non Hodgkin lymphomas were studied. Of
these, 119 (98.3%) were B cell lymphomas and 2 (1.7%)
were T cell lymphomas. This large majority of B cell lym-
phomas in our series is similar to what Cool and others
found in their study in Kenya where the majority were B
cell lymphomas[30].
The B cell lymphomas were classified as Burkitt lym-
phoma(95), diffuse large B cell lymphoma(19), mantle cell
lymphoma(4) and precursor B lymphoblastic lym-
phoma(1) as we reported previously[22].
The prevalence of Epstein Barr virus (EBV) was very
high among B cell lymphomas particularly Burkitt lym-
phoma. This is not surprising as it has been previously
reported by Olweny and others [31-33]. However, the dif-
fuse large B cell lymphomas (DLBCL) showed weaker
EBV association of 44.4%. This is similar to what Cool
found in neighbouring Kenya: 43% prevalence[30].
Children who were less than ten years of age were more
likely to have EBV. Since most of the children had Burkitt
lymphoma, this partly explains this stronger childhood
EBV association in our study. Lazzi found that Kenyan
children less than 15 years with Burkitt lymphoma had
94% EBV positivity[34]. Previous studies have also shown
much earlier transmission of EBV in the African popula-
tion as compared to the United States and Europe[35].
Geser and others also found that children that eventually
developed Burkitt lymphoma had two times higher anti-
body titres to EBV as compared to those that did not[36].
There were no significant differences as regards gender
and EBV association. This is not surprising since we
know that EBV is acquired mainly horizontally by inti-
mate contact[37]. More than 90% of the world's popula-
tion carry EBV as a lifelong, latent infection of B
lymphocytes[38].
As regards anatomical site of tumour presentation, all
the tumors arising in the jaw, abdomen and kidney were
EBV positive. These extranodal tumors were mainly
endemic Burkitt lymphomas that are strongly associated
with EBV[31]. However, there were no similar studies
relating EBV status to anatomical site with which we
could compare our findings. The nodal tumors had a
weaker association with EBV-these were mainly diffuse
large B cell lymphomas. This could be due to differences
in the mechanisms responsible for oncogenesis in the dif-
ferent lymphoma types[2]. None of the tumors tested had
Figure 1 Distribution of 107 B cell non Hodgkin lymphoma cases 
by gender and EBV test result, 1991-2000.
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Figure 2 Distribution of 107 B cell non Hodgkin lymphoma cases 
by age and EBV test result, 1991-2000.
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HHV8. This is not surprising since an earlier study by
Engels and colleges showed only one case of HHV8 posi-
tive lymphoma in Ugandan[39].
Using PCR, we did not find HIV in any of the Burkitt
lymphoma including the Burkitt lymphoma plasmacytoid
group that is associated with HIV in Western countries.
Only one of the Burkitt lymphomas diagnosed in the
period 2008-2009 had HIV. This is similar to what Parkin
found in his case control study in children with Burkitt
lymphoma[29].
Distinct pathways are involved in the molecular patho-
genesis of HIV-related NHLs. EBV is an important etio-
logical factor in a wide range of B cell lymphomas,
however its strongest association is with endemic Burkitt
lymphoma[7]. EBV associated B cell lymphomas arise as a
result of mutations and gene translocations that occur at
varying stages of differentiation. They express EBV latent
genes. There are three types of latency antigens that have
the ability to transform B cells, latent membrane protein
1 and 2(LMP-1 and 2) and Epstein Barr nuclear antigen-2
(EBNA-2)[18].
In DLBCL, LMP-1 is frequently expressed and plays a
crucial role in the transformation of B cells. It activates
the NFκβ, JNK, and p38 pathways by recruiting cellular
TRAF 1-3 and TRADD molecules to 2 short sequence
motifs CTAR-1 and CTAR-2 respectively, in the cytoplas-
mic domain of the LMP-1 molecule[2]. LMP-1 increases
the expression of the antiapoptotic proteins A20 and bcl-
2, the adherence molecule ICAM-1, the cell cycle regula-
tor p27Kip , and many others[40].
Evidence that the viral oncoprotein LMP-1 plays a role
in lymphoma pathogenesis has arisen from the observa-
t i o n  t h a t  k n o c k e d  d o w n  L M P - 1  c e l l  l i n e s  o f  A I D S -
DLBCL results in apoptosis. LMP-1 together with other
factors lead to the genetic damage that all contribute to
the pathogeneis of AIDS-DLBCL[41].
It seems that HHV8 and HIV have no role in the patho-
genesis of endemic Burkitt lymphoma. Recent studies
have shown that EBV is directly reactivated by P. falci-
parum antigens such as PfEMP1 during malaria infec-
tions. There is increased viral load leading to polyclonal B
cell activation and enhanced B cell survival which leads to
development of endemic BL in children living in malaria-
endemic areas[42].
Conclusion
The majority of the Burkitt lymphomas and only two
fifths of the diffuse large B cell lymphomas had EBV. All
the tumors were HHV8 negative. This study confirms the
very strong EBV association in Burkitt lymphoma.
Overall, the association of NHL with HIV was weaker
t h a n  w h a t  h a s  b e e n  r e p o r t e d  f r o m  o t h e r  c o u n t r i e s .
Improved treatment strategies for better outcomes in
HIV-associated B cell NHLs should be targeted towards
patients with DLBCL rather than Burkitt lymphoma.
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